Prognostic value of receptor activator of nuclear factor kappa-B (RANK) marker in patients with breast cancer

Despite notable progress made in studying breast cancer (BC), the mechanisms of metastases, in view of the classification into molecular subtypes, in patients with BC remain to be fully uninvestigated, in the presence of a good prognosis in particular. To study novel diagnostic and predictive marker...

Full description

Saved in:
Bibliographic Details
Main Authors: S. I. Zabroda, E. A. Maslyukova, L. I. Korytova, G. A. Raskin, K. M. Pozharissky, O. V. Korytov
Format: Article
Language:Russian
Published: ABV-press 2015-07-01
Series:Опухоли женской репродуктивной системы
Subjects:
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/428
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849773625433915392
author S. I. Zabroda
E. A. Maslyukova
L. I. Korytova
G. A. Raskin
K. M. Pozharissky
O. V. Korytov
author_facet S. I. Zabroda
E. A. Maslyukova
L. I. Korytova
G. A. Raskin
K. M. Pozharissky
O. V. Korytov
author_sort S. I. Zabroda
collection DOAJ
description Despite notable progress made in studying breast cancer (BC), the mechanisms of metastases, in view of the classification into molecular subtypes, in patients with BC remain to be fully uninvestigated, in the presence of a good prognosis in particular. To study novel diagnostic and predictive markers in a new way presents current problems in the pathology of BC. This investigation deals with the expression of osteoprotegerin (OPG) in the tumor cells of patients with BC. It enrolled 83 patients with locally advanced BC (T2–4N0–3M0) who had been treated in 2003 to 2010. The inclusion criterion was a histologically verified diagnosis of invasive BC. To study the level of OPG, the investigators conducted an immunohistochemical study of biopsy sections according to the standard protocol. The mean expression of receptor activator of nuclear factor kappa-B (RANK) in the BC cells was 18.7 %; itsmedian was 5 % (range, 0–90 %). The patients were divided into 2 groups according to the level of RANK expression: 1) high (higher than the median); 2) low (lower than the median). The high RANK group included 39 patients; the low RANK group comprised 44 patients. Analysis of the clinical and pathological characteristics of BC patients with regard RANK expression did not show any statistically significant differences in the presence or absence of affected regional lymph nodes, T category, and Ki-67 index. The analysis of clinical and pathomorphological and immunohistochemical characteristics in patients with breast cancer, taking into consideration RANK expression level, did not show any statistically significant differences with respect to presence or absence of affected regional lymph nodes, age, T category and Ki-67 index (р > 0.05). However, it revealed the following pattern: the high expression of RANK was more common in patients positive for estrogen and progesterone receptors than in those for negative receptors (p = 0.04).
format Article
id doaj-art-5fb4e36c884c46ccb1923ee2e6ec31a3
institution DOAJ
issn 1994-4098
1999-8627
language Russian
publishDate 2015-07-01
publisher ABV-press
record_format Article
series Опухоли женской репродуктивной системы
spelling doaj-art-5fb4e36c884c46ccb1923ee2e6ec31a32025-08-20T03:01:59ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272015-07-01112192410.17650/1994-4098-2015-11-2-19-24443Prognostic value of receptor activator of nuclear factor kappa-B (RANK) marker in patients with breast cancerS. I. Zabroda0E. A. Maslyukova1L. I. Korytova2G. A. Raskin3K. M. Pozharissky4O. V. Korytov5Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of Russia; 70 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Research Center for Radiology and Surgical Technologies, Ministry of Health of Russia; 70 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Research Center for Radiology and Surgical Technologies, Ministry of Health of Russia; 70 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Research Center for Radiology and Surgical Technologies, Ministry of Health of Russia; 70 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaRussian Research Center for Radiology and Surgical Technologies, Ministry of Health of Russia; 70 Leningradskaya St., Pesochnyi Settlement, Saint Petersburg, 197758, RussiaS.M. Kirov Military Medical Academy, Ministry of Defense of Russia; 6 Academician Lebedev St., Saint Petersburg, 195009, RussiaDespite notable progress made in studying breast cancer (BC), the mechanisms of metastases, in view of the classification into molecular subtypes, in patients with BC remain to be fully uninvestigated, in the presence of a good prognosis in particular. To study novel diagnostic and predictive markers in a new way presents current problems in the pathology of BC. This investigation deals with the expression of osteoprotegerin (OPG) in the tumor cells of patients with BC. It enrolled 83 patients with locally advanced BC (T2–4N0–3M0) who had been treated in 2003 to 2010. The inclusion criterion was a histologically verified diagnosis of invasive BC. To study the level of OPG, the investigators conducted an immunohistochemical study of biopsy sections according to the standard protocol. The mean expression of receptor activator of nuclear factor kappa-B (RANK) in the BC cells was 18.7 %; itsmedian was 5 % (range, 0–90 %). The patients were divided into 2 groups according to the level of RANK expression: 1) high (higher than the median); 2) low (lower than the median). The high RANK group included 39 patients; the low RANK group comprised 44 patients. Analysis of the clinical and pathological characteristics of BC patients with regard RANK expression did not show any statistically significant differences in the presence or absence of affected regional lymph nodes, T category, and Ki-67 index. The analysis of clinical and pathomorphological and immunohistochemical characteristics in patients with breast cancer, taking into consideration RANK expression level, did not show any statistically significant differences with respect to presence or absence of affected regional lymph nodes, age, T category and Ki-67 index (р > 0.05). However, it revealed the following pattern: the high expression of RANK was more common in patients positive for estrogen and progesterone receptors than in those for negative receptors (p = 0.04).https://ojrs.abvpress.ru/ojrs/article/view/428receptor activator of nuclear factor kappa-bosteoprotegerinreceptor activator of nuclear factor kappa-b ligandbreast cancerdistant metastasis
spellingShingle S. I. Zabroda
E. A. Maslyukova
L. I. Korytova
G. A. Raskin
K. M. Pozharissky
O. V. Korytov
Prognostic value of receptor activator of nuclear factor kappa-B (RANK) marker in patients with breast cancer
Опухоли женской репродуктивной системы
receptor activator of nuclear factor kappa-b
osteoprotegerin
receptor activator of nuclear factor kappa-b ligand
breast cancer
distant metastasis
title Prognostic value of receptor activator of nuclear factor kappa-B (RANK) marker in patients with breast cancer
title_full Prognostic value of receptor activator of nuclear factor kappa-B (RANK) marker in patients with breast cancer
title_fullStr Prognostic value of receptor activator of nuclear factor kappa-B (RANK) marker in patients with breast cancer
title_full_unstemmed Prognostic value of receptor activator of nuclear factor kappa-B (RANK) marker in patients with breast cancer
title_short Prognostic value of receptor activator of nuclear factor kappa-B (RANK) marker in patients with breast cancer
title_sort prognostic value of receptor activator of nuclear factor kappa b rank marker in patients with breast cancer
topic receptor activator of nuclear factor kappa-b
osteoprotegerin
receptor activator of nuclear factor kappa-b ligand
breast cancer
distant metastasis
url https://ojrs.abvpress.ru/ojrs/article/view/428
work_keys_str_mv AT sizabroda prognosticvalueofreceptoractivatorofnuclearfactorkappabrankmarkerinpatientswithbreastcancer
AT eamaslyukova prognosticvalueofreceptoractivatorofnuclearfactorkappabrankmarkerinpatientswithbreastcancer
AT likorytova prognosticvalueofreceptoractivatorofnuclearfactorkappabrankmarkerinpatientswithbreastcancer
AT garaskin prognosticvalueofreceptoractivatorofnuclearfactorkappabrankmarkerinpatientswithbreastcancer
AT kmpozharissky prognosticvalueofreceptoractivatorofnuclearfactorkappabrankmarkerinpatientswithbreastcancer
AT ovkorytov prognosticvalueofreceptoractivatorofnuclearfactorkappabrankmarkerinpatientswithbreastcancer